EGR1-dependent PTEN upregulation by 2-benzoyloxycinnamaldehyde attenuates cell invasion and EMT in colon cancer

Cancer Letters

Volumn 349, Issue 1, 2014, Pages 35-44

  Kim, Jinkyung ^a   Kang, Hye Suk ^a   Lee, Yu Jin ^b   Lee, Heon Jin ^a   Yun, Jieun ^b   Shin, Jung Hyu ^b   Lee, Chang Woo ^b   Kwon, Byoung Mog ^b   Hong, Su Hyung ^a  

^a Kyungpook National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

2' Benzoyloxycinnamaldehyde; Colon cancer; Early growth response protein 1 (EGR1); Epithelial mesenchymal transition (EMT); Metastasis; PTEN

Indexed keywords

2 BENZOYLOXYCINNAMALDEHYDE; BETA CATENIN; CINNAMALDEHYDE DERIVATIVE; EARLY GROWTH RESPONSE FACTOR 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; 2'-BENZOYLOXYCINNAMALDEHYDE; ACROLEIN; BENZOIC ACID DERIVATIVE; CADHERIN; EGR1 PROTEIN, HUMAN; PROTEIN KINASE B; PTEN PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CELL MIGRATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; METASTASIS POTENTIAL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; COLONIC NEOPLASMS; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

GASTROPODA; MUS;

ACROLEIN; ANIMALS; BENZOATES; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; EARLY GROWTH RESPONSE PROTEIN 1; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; UP-REGULATION;

EID: 84901059845     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.03.025     Document Type: Article

References (55)

1. Kwon B.M., Lee S.H., Cho Y.K., Bok S.H., So S.H., Yoon M.R., S.I.C. Synthesis and biological activity of cinnamaldehydes as angiogenesis inhibitors. Bioorg. Med. Chem. Lett. 1997, 7:2473-2476.
2. Kwon B.M., Cho Y.K., Lee S.H., Nam J.Y., Bok S.H., Chun S.K., Kim J.A., Lee I.R. 2'-Hydroxycinnamaldehyde from stem bark of Cinnamomum cassia. Planta Med. 1996, 62:183-184.
3. Han D.C., Lee M.Y., Shin K.D., Jeon S.B., Kim J.M., Son K.H., Kim H.C., Kim H.M., Kwon B.M. 2'-Benzoyloxycinnamaldehyde induces apoptosis in human carcinoma via reactive oxygen species. J. Biol. Chem. 2004, 279:6911-6920.
4. Hong S.H., Kim J., Kim J.M., Lee S.Y., Shin D.S., Son K.H., Han D.C., Sung Y.K., Kwon B.M. Apoptosis induction of 2'-hydroxycinnamaldehyde as a proteasome inhibitor is associated with ER stress and mitochondrial perturbation in cancer cells. Biochem. Pharmacol. 2007, 74:557-565.
5. Ock J., Lee H.A., Ismail I.A., Lee H.J., Kwon B.M., Suk K., Lee W.H., Hong S.H. Differential antiproliferation effect of 2'-benzoyloxycinnamaldehyde in K-ras-transformed cells via downregulation of thiol antioxidants. Cancer Sci. 2011, 102:212-218.
6. Moon E.Y., Lee M.R., Wang A.G., Lee J.H., Kim H.C., Kim H.M., Kim J.M., Kwon B.M., Yu D.Y. Delayed occurrence of H-ras12V-induced hepatocellular carcinoma with long-term treatment with cinnamaldehydes. Eur. J. Pharmacol. 2006, 530:270-275.
7. Ismail I.A., Kang H.S., Lee H.J., Chang H., Yun J., Lee C.W., Kim N.H., Kim H.S., Yook J.I., Hong S.H., Kwon B.M. 2-Hydroxycinnamaldehyde inhibits the epithelial-mesenchymal transition in breast cancer cells. Breast Cancer Res. Treat. 2013, 137:697-708.
8. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 2006, 12:895-904.
9. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8:806-823.
10. Nieto M.A. The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 2002, 3:155-166.
11. Lim R.W., Varnum B.C., Herschman H.R. Cloning of tetradecanoyl phorbol ester-induced 'primary response' sequences and their expression in density-arrested Swiss 3T3 cells and a TPA non-proliferative variant. Oncogene 1987, 1:263-270.
12. Christy B.A., Lau L.F., Nathans D. A gene activated in mouse 3T3 cells by serum growth factors encodes a protein with "zinc finger" sequences. Proc. Natl. Acad. Sci. USA 1988, 85:7857-7861.
13. Calogero A., Arcella A., De Gregorio G., Porcellini A., Mercola D., Liu C., Lombari V., Zani M., Giannini G., Gagliardi F.M., Caruso R., Gulino A., Frati L., Ragona G. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Clin. Cancer Res. 2001, 7:2788-2796.
14. Levin W.J., Press M.F., Gaynor R.B., Sukhatme V.P., Boone T.C., Reissmann P.T., Figlin R.A., Holmes E.C., Souza L.M., Slamon D.J. Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The lung cancer study group. Oncogene 1995, 11:1261-1269.
15. Eid M.A., Kumar M.V., Iczkowski K.A., Bostwick D.G., Tindall D.J. Expression of early growth response genes in human prostate cancer. Cancer Res. 1998, 58:2461-2468.
16. Kuo P.L., Chen Y.H., Chen T.C., Shen K.H., Hsu Y.L. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway. J. Cell Physiol. 2011, 226:1224-1231.
17. Mora G.R., Olivier K.R., Cheville J.C., Mitchell R.F., Lingle W.L., Tindall D.J. The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate. Mol. Cancer Res. 2004, 2:115-128.
18. Kang H.S., Ock J., Lee H.J., Lee Y.J., Kwon B.M., Hong S.H. Early growth response protein 1 upregulation and nuclear translocation by 2'-benzoyloxycinnamaldehyde induces prostate cancer cell death. Cancer Lett. 2013, 329:217-227.
19. Shingu T., Bornstein P. Overlapping Egr-1 and Sp1 sites function in the regulation of transcription of the mouse thrombospondin 1 gene. J. Biol. Chem. 1994, 269:32551-32557.
20. Liu C., Yao J., Mercola D., Adamson E. The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J. Biol. Chem. 2000, 275:20315-20323.
21. Sarver A.L., Li L., Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res. 2010, 70:9570-9580.
22. Okamura H., Yoshida K., Morimoto H., Haneji T. PTEN expression elicited by EGR-1 transcription factor in calyculin A-induced apoptotic cells. J. Cell Biochem. 2005, 94:117-125.
23. Virolle T., Adamson E.D., Baron V., Birle D., Mercola D., Mustelin T., de Belle I. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat. Cell Biol. 2001, 3:1124-1128.
24. Kim S.O., Kwon J.I., Jeong Y.K., Kim G.Y., Kim N.D., Choi Y.H. Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of beta-lapachone in human hepatocarcinoma cells. Biosci. Biotechnol. Biochem. 2007, 71:2169-2176.
25. Lucerna M., Pomyje J., Mechtcheriakova D., Kadl A., Gruber F., Bilban M., Sobanov Y., Schabbauer G., Breuss J., Wagner O., Bischoff M., Clauss M., Binder B.R., Hofer E. Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res. 2006, 66:6708-6713.
26. Langlois M.J., Bergeron S., Bernatchez G., Boudreau F., Saucier C., Perreault N., Carrier J.C., Rivard N. The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression. PLoS One 2010, 5:e15742.
27. Zhou X.P., Loukola A., Salovaara R., Nystrom-Lahti M., Peltomaki P., de la Chapelle A., Aaltonen L.A., Eng C. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am. J. Pathol. 2002, 161:439-447.
28. Jiang Y.A., Fan L.F., Jiang C.Q., Zhang Y.Y., Luo H.S., Tang Z.J., Xia D., Wang M. Expression and significance of PTEN, hypoxia-inducible factor-1 alpha in colorectal adenoma and adenocarcinoma. World J. Gastroenterol. 2003, 9:491-494.
29. Colakoglu T., Yildirim S., Kayaselcuk F., Nursal T.Z., Ezer A., Noyan T., Karakayali H., Haberal M. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?. Am. J. Surg. 2008, 195:719-725.
30. Rychahou P.G., Kang J., Gulhati P., Doan H.Q., Chen L.A., Xiao S.Y., Chung D.H., Evers B.M. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc. Natl. Acad. Sci. USA 2008, 105:20315-20320.
31. Sly L.M., Rauh M.J., Kalesnikoff J., Buchse T., Krystal G. SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide. Exp. Hematol. 2003, 31:1170-1181.
32. Hoekstra E., Peppelenbosch M.P., Fuhler G.M. The role of protein tyrosine phosphatases in colorectal cancer. Biochim. Biophys. Acta 1826, 2012:179-188.
33. Leslie N.R., Batty I.H., Maccario H., Davidson L., Downes C.P. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 2008, 27:5464-5476.
34. Mohanam S., Sawaya R., McCutcheon I., Ali-Osman F., Boyd D., Rao J.S. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 1993, 53:4143-4147.
35. Sadanandam A., Lyssiotis C.A., Homicsko K., Collisson E.A., Gibb W.J., Wullschleger S., Ostos L.C., Lannon W.A., Grotzinger C., Del Rio M., Lhermitte B., Olshen A.B., Wiedenmann B., Cantley L.C., Gray J.W., Hanahan D. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 2013, 19:619-625.
36. Hewitt R.E., McMarlin A., Kleiner D., Wersto R., Martin P., Tsokos M., Stamp G.W., Stetler-Stevenson W.G. Validation of a model of colon cancer progression. J. Pathol. 2000, 192:446-454.
37. Ma C., Rong Y., Radiloff D.R., Datto M.B., Centeno B., Bao S., Cheng A.W., Lin F., Jiang S., Yeatman T.J., Wang X.F. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 2008, 22:308-321.
38. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego, Calif.) 2001, 25:402-408.
39. Kwon H.K., Hwang J.S., So J.S., Lee C.G., Sahoo A., Ryu J.H., Jeon W.K., Ko B.S., Im C.R., Lee S.H., Park Z.Y., Im S.H. Cinnamon extract induces tumor cell death through inhibition of NFkappaB and AP1. BMC Cancer 2010, 10:392.
40. Lee C.W., Lee S.H., Lee J.W., Ban J.O., Lee S.Y., Yoo H.S., Jung J.K., Moon D.C., Oh K.W., Hong J.T. 2-Hydroxycinnamaldehyde inhibits SW620 colon cancer cell growth through AP-1 inactivation. J. Pharmacol. Sci. 2007, 104:19-28.
41. Ka H., Park H.J., Jung H.J., Choi J.W., Cho K.S., Ha J., Lee K.T. Cinnamaldehyde induces apoptosis by ROS-mediated mitochondrial permeability transition in human promyelocytic leukemia HL-60 cells. Cancer Lett. 2003, 196:143-152.
42. Yamamoto C., Basaki Y., Kawahara A., Nakashima K., Kage M., Izumi H., Kohno K., Uramoto H., Yasumoto K., Kuwano M., Ono M. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res. 2010, 70:8715-8725.
43. Tice D.A., Soloviev I., Polakis P. Activation of the Wnt pathway interferes with serum response element-driven transcription of immediate early genes. J. Biol. Chem. 2002, 277:6118-6123.
44. Polakis P. Wnt signaling and cancer. Genes Dev. 2000, 14:1837-1851.
45. Kotelevets L., van Hengel J., Bruyneel E., Mareel M., van Roy F., Chastre E. The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J. Cell Biol. 2001, 155:1129-1135.
46. Yamada K.M., Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci. 2001, 114:2375-2382.
47. Persad S., Troussard A.A., McPhee T.R., Mulholland D.J., Dedhar S. Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J. Cell Biol. 2001, 153:1161-1174.
48. Cheng G.Z., Park S., Shu S., He L., Kong W., Zhang W., Yuan Z., Wang L.H., Cheng J.Q. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr. Cancer Drug Targets 2008, 8:2-6.
49. Larue L., Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005, 24:7443-7454.
50. Yan D., Avtanski D., Saxena N.K., Sharma D. Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires beta-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J. Biol. Chem. 2012, 287:8598-8612.
51. Taurin S., Sandbo N., Qin Y., Browning D., Dulin N.O. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J. Biol. Chem. 2006, 281:9971-9976.
52. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., Haug J.S., Rupp D., Porter-Westpfahl K.S., Wiedemann L.M., Wu H., Li L. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006, 441:518-522.
53. Perry J.M., He X.C., Sugimura R., Grindley J.C., Haug J.S., Ding S., Li L. Cooperation between both Wnt/{beta}-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev. 2011, 25:1928-1942.
54. Bowen K.A., Doan H.Q., Zhou B.P., Wang Q., Zhou Y., Rychahou P.G., Evers B.M. PTEN loss induces epithelial-mesenchymal transition in human colon cancer cells. Anticancer Res. 2009, 29:4439-4449.
55. Van Meir E.G., Hadjipanayis C.G., Norden A.D., Shu H.K., Wen P.Y., Olson J.J. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010, 60:166-193.